PPARG and hepatocellular carcinoma: Most interestingly, there have been encouraging reports revealing that PPARγ activation prevents cancer in tissues such as colon, breast, prostate, lung and liver [14], justifying that PPARγ agonists may be useful in hepatocellular carcinoma therapy [15].